Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Medical News
  3. Nephrology

Pazopanib Shows Activity in EWSR1-NFATC2 Bone Sarcoma

ReachMD Healthcare Image
01/15/2024
News Faviconmiragenews.com

"Pazopanib is a multi-kinase inhibitor that is currently approved for treatment of advanced renal cell carcinoma and chemotherapy-refractory soft tissue sarcoma."

BUFFALO, NY- January 12, 2024 – A new case report was published in Oncoscience (Volume 10) on September 20, 2023, entitled, "Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma."

Pazopanib, a multi-kinase VEGF inhibitor, is currently FDA approved for advanced renal cell carcinoma and advanced soft tissue sarcoma; but limited evidence exists on its efficacy in bone sarcomas.

In this case report, researchers Mohamed A. Gouda, Maria A. Zarzour, Ara A. Vaporciyan, Kalevi Kairemo, Hubert H. Chuang, and Vivek Subbiah from The University of Texas MD Anderson Cancer Center and Sarah Cannon Research Institute discuss the case of a patient with a EWSR1-NFATC2 fusion positive bone sarcoma who had exceptional tumor control through using pazopanib and surgery for an overall duration exceeding 5 years. The report also reviews the literature on EWSR1-NFATC2 translocation-associated sarcomas and use of pazopanib in bone sarcomas.

"In brief, this case, in accordance with previously reported evidence, provides proof of activity of pazopanib in EWSR1-NFATC2 positive sarcoma. The report shows that pazopanib when administered in an adjuvant capacity demonstrated its effectiveness in preventing or delaying the progression of additional metastasis. Nevertheless, due to the adjuvant nature of the treatment, it remains uncertain whether this approach would have resulted in tumor shrinkage. Further pre-clinical studies and clinical studies using pazopanib in EWSR1-NFATC2 sarcomas are warranted."

Read the full paper: DOI: https://doi.org/10.18632/oncoscience.587

Correspondence to: Vivek Subbiah

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full

here

.

Schedule2 Dec 2024